SYK
ENSG00000165025
Target class
Kinase
Chromosome
9
Approved drugs
2
Clinical candidates (approved and in development)
14
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- Yes
- Target name
- SYK
- Gene name
- Spleen associated tyrosine kinase
- Gene symbol
- SYK
- Protein name
- Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase) (p72-Syk)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Syk family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 46
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 77.38
- Tissue specificity (Gini)
- 0.636
- Tissue specificity (tau)
- 0.871
- KEGG gene identifiers
- hsa:6850
- Protein interaction confidence
- 0.883409
- Protein interaction partners
- 137
- R-HSA-114604
- R-HSA-2029481
- R-HSA-2029482
- R-HSA-2029485
- R-HSA-2424491
- R-HSA-2454202
- R-HSA-2730905
- R-HSA-2871796
- R-HSA-2871809
- R-HSA-354192
- R-HSA-5607764
- R-HSA-5621480
- R-HSA-9020558
- R-HSA-912631
- R-HSA-9664323
- R-HSA-9664422
- R-HSA-9674555
- R-HSA-9679191
- R-HSA-9705462
- R-HSA-9706374
- R-HSA-983695
- End position
- 90898549
- Start position
- 90801579
- Chromosome
- 9
- Strand
- Forward
- Cell membrane . Cytoplasm, cytosol .
- Cytosol
- Plasma membrane
- Vesicles
- Tissue specificity (tau)
- 0.871285
- Expression inequality (Gini)
- 0.636146
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 77.38
- Spleen
- 72.28
- Whole Blood
- 68.87
- Thyroid
- 43.54
- Small Intestine - Terminal Ileum
- 35.34
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes77.38
- Spleen72.28
- Whole Blood68.87
- Thyroid43.54
- Small Intestine - Terminal Ileum35.34
- Esophagus - Mucosa27.18
- Lung23.84
- Vagina17.83
- Skin - Sun Exposed (Lower leg)16.56
- Colon - Transverse16.32
- Skin - Not Sun Exposed (Suprapubic)15.65
- Testis13.31
- Kidney - Medulla12.69
- Minor Salivary Gland11.18
- Adipose - Subcutaneous9.54
- Kidney - Cortex8.5
- Nerve - Tibial8.23
- Adipose - Visceral (Omentum)7.66
- Artery - Coronary7.61
- Breast - Mammary Tissue7.27
- Prostate7.08
- Stomach7.07
- Bladder6.78
- Pancreas6.34
- Brain - Spinal cord (cervical c-1)6.06
And 29 more, listed on the interactive page.
- GO:0002223
- GO:0002752
- GO:0002862
- GO:0006357
- GO:0006468
- GO:0006606
- GO:0007159
- GO:0009887
- GO:0010803
- GO:0030168
- GO:0030593
- GO:0031334
- GO:0032733
- GO:0032735
- GO:0032755
- GO:0032757
- GO:0032760
- GO:0032930
- GO:0034165
- GO:0035556
- GO:0038095
- GO:0038096
- GO:0045579
- GO:0050729
- GO:0050853
And 6 more, listed on the interactive page.
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0032991
- GO:0042101
- GO:0001784
- GO:0004672
- GO:0004674
- GO:0004713
- GO:0004715
- GO:0005102
- GO:0005178
- GO:0005515
- GO:0016170
- GO:0016301
- GO:0043274
- GO:0097110
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hSyk, is one of one assay component(s) measured or calculated from the NVS_ENZ_hSyk assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (186)
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
- A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
- A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis
- A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
- A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
- A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
- A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
- A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
- A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
- A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Drugs (20)
- Apitolisib
- Cerdulatinib Tyrosine-protein kinase SYK inhibitor
- Entospletinib Tyrosine-protein kinase SYK inhibitor
- Fostamatinib Tyrosine-protein kinase SYK inhibitor
- Fostamatinib disodium Tyrosine-protein kinase SYK inhibitor
- Gusacitinib Tyrosine-protein kinase SYK inhibitor
- Gusacitinib hydrochloride Tyrosine-protein kinase SYK inhibitor
- Lanraplenib Tyrosine-protein kinase SYK inhibitor
- Lanraplenib succinate Tyrosine-protein kinase SYK inhibitor
- Lazertinib
- Mivavotinib Tyrosine-protein kinase SYK inhibitor
- Mivavotinib citrate Tyrosine-protein kinase SYK inhibitor
- PRT-2607 Tyrosine-protein kinase SYK inhibitor
- R-112 Tyrosine-protein kinase SYK inhibitor
- R-333 Tyrosine-protein kinase SYK inhibitor
- R-343 Tyrosine-protein kinase SYK inhibitor
- R-348 Tyrosine-protein kinase SYK inhibitor
- R-406 Tyrosine-protein kinase SYK inhibitor
- Sovleplenib Tyrosine-protein kinase SYK inhibitor
- Sovleplenib acetate Tyrosine-protein kinase SYK inhibitor